ArticleBMC geriatrics2025
NT-proBNP changes predict outcomes in elderly type 2 myocardial infarction patients.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN-terminal pro-B-type natriuretic peptide (NT-proBNP) is useful to predict adverse outcomes. Change in NT-proBNP level may provide additional actionable risk assessment information. This study aimed to determine the association of change in NT-proBNP level with adverse outcomes among elderly individuals with type 2 myocardial infarction (MI).
methodsA retrospective analysis was conducted among elderly individuals with type 2 MI between December 2010 and December 2022. Change of NT-proBNP level was determined as the difference between the baseline and last measurement obtained during the period of 30 days.
resultsA total of 3007 participants aged 80 years and older were included. The patients were divided in accordance with the change in NT-proBNP level into those with NT-proBNP change ≥ 30% decrease, NT-proBNP change < 30% decrease and ≤ 10% increase, and NT-proBNP change > 10% increase. The patients with NT-proBNP change > 10% increase were older, had higher systolic blood pressure, loop diuretics use, and higher incidence of atrial fibrillation and chronic kidney disease. The quartile of change in NT-proBNP > 10% increase was markedly associated with increased risk of incident HF, as well as all-cause and cardiovascular mortality. The incidence rate of mortality increased in a graded fashion with change in NT-proBNP level. The Kaplan-Meier event-free curves showed that patients with NT-proBNP change > 10% increase had the highest risk, followed by those with NT-proBNP change < 30% decrease and ≤ 10% increase, and NT-proBNP change ≥ 30% decrease.
conclusionsThe change in NT-proBNP level can be used for identifying patients at a high risk of incident HF, as well as cardiovascular and all-cause mortality in elderly individuals with type 2 MI. It may be a promising biomarker to guide personalized therapy optimization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.